Medicare Enrolled
Dr. Matthew Taub, M.D.
Hematology & Oncology · Pembroke Pines, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Taub from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Taub?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Taub
Dr. Matthew Taub is a hematology & oncology specialist in Pembroke Pines, FL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Taub performed 8,937 Medicare services across 1,176 unique beneficiaries.
Between the years covered by Open Payments, Dr. Taub received a total of $29,400 from 92 pharmaceutical and/or device companies across 1343 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Taub is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 26% volume in FL
$29,400 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 82721 | Clear | January 31, 2027 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗8,937
Medicare services
Top 26% in FL for hematology & oncology
1,176
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~470 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,751 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 1,910 | $0 | $0 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,369 | $65 | $95 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
708 | $100 | $140 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
426 | $5 | $5 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
406 | $8 | $15 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
233 | $106 | $200 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
133 | $23 | $100 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
132 | $180 | $245 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
131 | $105 | $250 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
125 | $1 | $2 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
114 | $42 | $75 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
92 | $53 | $80 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
92 | $95 | $125 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
77 | $11 | $25 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
67 | $23 | $200 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
49 | $53 | $100 |
| New patient office visit, complex (60-74 min) | 44 | $178 | $240 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
33 | $136 | $350 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
19 | $71 | $150 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
15 | $74 | $100 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
11 | $139 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.5% high complexity
55.2% medium
40.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$29,400
Total received (2018-2024)
Avg $4,200/year across 7 years
Top 20% in FL for hematology & oncology
92
Companies
1,343
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$26,239 (89.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,175 (7.4%)
Other
Charitable contributions, space rental, and other categories
$987 (3.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,199
2023
$5,176
2022
$4,388
2021
$5,633
2020
$3,246
2019
$2,990
2018
$2,768
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$2,951
PFIZER INC.
$2,615
Janssen Biotech, Inc.
$1,916
AstraZeneca Pharmaceuticals LP
$1,809
E.R. Squibb & Sons, L.L.C.
$1,744
Pharmacosmos Therapeutics Inc.
$1,556
Celgene Corporation
$1,458
Rigel Pharmaceuticals, Inc.
$982
Genentech USA, Inc.
$813
Daiichi Sankyo Inc.
$758
Amgen Inc.
$712
Merck Sharp & Dohme Corporation
$704
Incyte Corporation
$615
Myriad Genetic Laboratories, Inc.
$482
Merck Sharp & Dohme LLC
$478
Seagen Inc.
$475
Lilly USA, LLC
$460
Karyopharm Therapeutics Inc.
$430
EMD Serono, Inc.
$398
GENZYME CORPORATION
$398
ARRAY BIOPHARMA INC
$386
GlaxoSmithKline, LLC.
$358
Takeda Pharmaceuticals U.S.A., Inc.
$350
Kite Pharma, Inc.
$323
Eisai Inc.
$322
Regeneron Healthcare Solutions, Inc.
$267
BeiGene USA, Inc.
$267
Astellas Pharma US Inc
$264
Adaptive Biotechnologies Corporation
$256
Bayer HealthCare Pharmaceuticals Inc.
$253
PharmaEssentia USA Corporation
$218
Dova Pharmaceuticals
$211
ABBVIE INC.
$204
Taiho Oncology, Inc.
$203
Seattle Genetics, Inc.
$191
Stemline Therapeutics Inc.
$150
TAIHO ONCOLOGY, INC.
$142
Mirati Therapeutics, Inc.
$141
Teva Pharmaceuticals USA, Inc.
$139
Alexion Pharmaceuticals, Inc.
$134
Aveo Pharmaceuticals, Inc.
$123
Exelixis Inc.
$113
Ipsen Biopharmaceuticals, Inc
$112
JAZZ PHARMACEUTICALS INC.
$111
Global Blood Therapeutics, Inc.
$107
Octapharma USA, Inc.
$106
Kyowa Kirin, Inc.
$100
Clovis Oncology, Inc.
$99
AbbVie Inc.
$97
Bayer Healthcare Pharmaceuticals Inc.
$93
Sun Pharmaceutical Industries Inc.
$90
Gilead Sciences, Inc.
$80
Janssen Pharmaceuticals, Inc
$77
Emmaus Medical, Inc.
$74
EISAI INC.
$73
Fennec Pharmaceuticals, Inc.
$70
TerSera Therapeutics LLC
$69
Mylan Institutional Inc.
$68
Helsinn Therapeutics (U.S.), Inc.
$68
CTI BioPharma Corp.
$65
Deciphera Pharmaceuticals Inc.
$64
Agios Pharmaceuticals, Inc.
$64
Boston Scientific Corporation
$62
Epizyme, Inc.,
$60
Janssen Scientific Affairs, LLC
$58
Otsuka America Pharmaceutical, Inc.
$53
Dendreon Pharmaceuticals LLC
$47
Aurobindo Pharma USA, Inc.
$46
Organon LLC
$45
Pharmacyclics LLC, An AbbVie Company
$43
Myovant Sciences Inc.
$42
Tempus AI, Inc
$39
Coherus Biosciences Inc.
$38
Sirtex Medical Inc
$37
EUSA Pharma (US) LLC
$35
GE HealthCare
$29
Alnylam Pharmaceuticals Inc.
$27
Sumitomo Pharma America, Inc.
$26
G1 Therapeutics, Inc.
$23
ADC Therapeutics America, Inc.
$22
Genmab U.S., Inc.
$22
Apellis Pharmaceuticals, Inc.
$21
Cumberland Pharmaceuticals, Inc.
$20
Pharmacyclics LLC, an AbbVie Company
$19
Jazz Pharmaceuticals Inc.
$19
Shire North American Group Inc
$17
Verastem, Inc.
$16
Advanced Accelerator Applications
$16
Menarini Silicon Biosystems, Inc.
$15
SANOFI-AVENTIS U.S. LLC
$14
AbbVie, Inc.
$14
Stryker Corporation
$14
Top 3 companies account for 25.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · AKEEGA · AKYNZEO · ALIMTA · ALUNBRIG · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CERDELGA · CHANTIX · COSELA · CYRAMZA · Cabometyx · Cellsearch · Columvi · Copiktra · DARZALEX · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EXKIVITY · Empaveli · Endari · Enhertu · Epkinly · Erleada · FOTIVDA · FRUZAQLA · Fabhalta · Folotyn · Fulphila · GAZYVA · GIVLAARI · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INQOVI · INREBIC · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · MYRISK · Marqibo · Monoferric · NEXPLANON · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ODOMZO · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · ORTHOLOC 2 LAPIFUSE · OXBRYTA · Ogivri · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · PRECISETUMOR · PROMACTA · PROVENGE · PYRUKYND · Padcev · Pedmark · Phesgo · Polivy · Pomalyst · Poteligeo · QINLOCK · Quzyttir · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · TheraSphere Y90 Glass Microspheres 10 GBq · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VONVENDI · VOTRIENT · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · YONSA · Yescarta · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $329 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
201
Per 100K population
10.3
County median income
$74,534
Nearest hospital
SOUTH FLORIDA STATE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Taub is a mixed practice specialist, with above-average Medicare volume (top 26% in FL), with low-engagement industry engagement in the top 20% of FL peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Taub experienced with dexamethasone injection (steroid)?
Based on Medicare claims data, Dr. Taub performed 2,751 dexamethasone injection (steroid) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Taub receive payments from pharmaceutical companies?
Yes. Dr. Taub received a total of $29,400 from 92 companies across 1,343 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Taub's costs compare to other hematology & oncology specialists in Pembroke Pines?
Dr. Taub's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Taub) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Pembroke Pines
Browse hematology & oncology specialists in Pembroke Pines ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology